Ruxolitinib treatment in patients with polycythemia vera reduces variant allele frequency and improves symptom burden and hematocrit control.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
371 patients, mean V617F allele burden declined from baseline (ruxolitinib, 66.
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
[CONCLUSION] Patients receiving ruxolitinib experienced decreased V617F allele burden, durable hematocrit control, and better symptom improvements versus BAT, reinforcing ruxolitinib clinical benefit. [TRIAL REGISTRATION] RESPONSE: https://clinicaltrials.gov/study/NCT01243944; RESPONSE-2: https://clinicaltrials.gov/study/NCT02038036.
[BACKGROUND] In RESPONSE/RESPONSE-2, ruxolitinib was superior to best available therapy (BAT) in patients with polycythemia vera (PV).
APA
Harrison CN, Kiladjian JJ, et al. (2026). Ruxolitinib treatment in patients with polycythemia vera reduces variant allele frequency and improves symptom burden and hematocrit control.. Therapeutic advances in hematology, 17, 20406207261425083. https://doi.org/10.1177/20406207261425083
MLA
Harrison CN, et al.. "Ruxolitinib treatment in patients with polycythemia vera reduces variant allele frequency and improves symptom burden and hematocrit control.." Therapeutic advances in hematology, vol. 17, 2026, pp. 20406207261425083.
PMID
41890273 ↗
Abstract 한글 요약
[BACKGROUND] In RESPONSE/RESPONSE-2, ruxolitinib was superior to best available therapy (BAT) in patients with polycythemia vera (PV).
[OBJECTIVE] Report a post hoc pooled RESPONSE/RESPONSE-2 analysis.
[DESIGN] RESPONSE/RESPONSE-2 were randomized, open-label phase III trials. Adults with hydroxyurea-resistant/intolerant PV were randomized 1:1 to ruxolitinib or BAT; crossover to ruxolitinib was allowed after primary analysis.
[METHODS] V617F allele burden, hematocrit control, and Myeloproliferative Neoplasm Symptom Assessment Form total symptom score (MPN-SAF TSS) were assessed.
[RESULTS] Among 371 patients, mean V617F allele burden declined from baseline (ruxolitinib, 66.1%; crossover, 69.5%) through week 208 (41.4%; 37.1%). Significantly more ruxolitinib versus BAT patients achieved hematocrit control at week 28 (62.0% vs 18.2%; < 0.0001) and ⩾50% reduction in MPN-SAF TSS at week 16 (48.7% vs 18.0%; < 0.0001).
[CONCLUSION] Patients receiving ruxolitinib experienced decreased V617F allele burden, durable hematocrit control, and better symptom improvements versus BAT, reinforcing ruxolitinib clinical benefit.
[TRIAL REGISTRATION] RESPONSE: https://clinicaltrials.gov/study/NCT01243944; RESPONSE-2: https://clinicaltrials.gov/study/NCT02038036.
[OBJECTIVE] Report a post hoc pooled RESPONSE/RESPONSE-2 analysis.
[DESIGN] RESPONSE/RESPONSE-2 were randomized, open-label phase III trials. Adults with hydroxyurea-resistant/intolerant PV were randomized 1:1 to ruxolitinib or BAT; crossover to ruxolitinib was allowed after primary analysis.
[METHODS] V617F allele burden, hematocrit control, and Myeloproliferative Neoplasm Symptom Assessment Form total symptom score (MPN-SAF TSS) were assessed.
[RESULTS] Among 371 patients, mean V617F allele burden declined from baseline (ruxolitinib, 66.1%; crossover, 69.5%) through week 208 (41.4%; 37.1%). Significantly more ruxolitinib versus BAT patients achieved hematocrit control at week 28 (62.0% vs 18.2%; < 0.0001) and ⩾50% reduction in MPN-SAF TSS at week 16 (48.7% vs 18.0%; < 0.0001).
[CONCLUSION] Patients receiving ruxolitinib experienced decreased V617F allele burden, durable hematocrit control, and better symptom improvements versus BAT, reinforcing ruxolitinib clinical benefit.
[TRIAL REGISTRATION] RESPONSE: https://clinicaltrials.gov/study/NCT01243944; RESPONSE-2: https://clinicaltrials.gov/study/NCT02038036.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Raman-guided analysis of drug response combined with chemometrics helps monitor the effect of ruxolitinib on acute lymphoblastic leukemia.
- Cost-Effectiveness Analysis of Ritlecitinib Compared With No Treatment in Patients With Severe Alopecia Areata in Japan.
- Propranolol enhances the oncolytic effect of newcastle disease virus on canine mammary tumor cell by modulating the IFN-I-mediated JAK-STAT signaling pathway.
- Evaluation of immunohistochemical and gene expression of Janus kinase 1 and Janus kinase 3 in the skin of different clinical types of mycosis fungoides patients - Part 1.
- Safety of upadacitinib in atopic dermatitis in randomized clinical trials across 6 years.
- Allicin inhibits PD-L1 through the IL-6/JAK2/STAT3 pathway to suppress immune evasion in osteosarcoma.